Trial Profile
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 19 Feb 2022 Primary endpoint has not been met. (Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies [ Time Frame: Baseline to up to 14 days after the last dose ]), as per Results presented at the 2022 Genitourinary Cancers Symposium
- 19 Feb 2022 Primary endpoint has not been met. (Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies [ Time Frame: Baseline to up to 14 days after the last dose ]), as per Results presented at the 2022 Genitourinary Cancers Symposium